T

TransMedics

Ex-vivo organ perfusion platform

IT Business Partner - Finance & HR

Full-TimePosted on 7/24/2026
$147.2k - $183.6k+ Bonus + Equity
Mid
Bachelor's
Andover, MA, USA
In PersonHeadquarters are planned to relocate to Somerville, Massachusetts by 2028; timing and role impact may vary.
IT OperationsEnterprise Applications
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in Information Systems is required.
  • A strong understanding of Finance and HR operations, compliance requirements, and data governance is required.
  • Ability to define business processes and translate them into system requirements across multiple platforms is required.
  • Experience with software testing, validation, and requirements documentation is required.
  • Ability to work independently and drive initiatives as an individual contributor is required.
  • Ability to manage complex projects and influence stakeholders across Finance, HR, and IT functions is required.
  • Ability to translate technical concepts into business language for diverse audiences is required.
  • Strong communication, documentation, and problem-solving skills are required.
Responsibilities
  • Help define and execute the enterprise-systems roadmap supporting Finance and HR, aligned with business priorities and company growth.
  • Partner with IT and technical teams to translate business needs into system enhancements, configurations, and delivered solutions.
  • Prioritize system improvements and new capabilities based on business value, risk, scalability, and user impact.
  • Ensure enterprise platforms integrate effectively with third-party systems such as payroll, benefits, procurement, project accounting, learning, and reporting tools.
  • Define success criteria for system enhancements and ensure solutions deliver measurable business value.
  • Promote adoption and effective use of enterprise-system capabilities across the organization.
  • Partner with Finance and HR leaders to understand business objectives and identify opportunities to improve processes through technology.
  • Lead requirements gathering, process mapping, and documentation efforts for enterprise-system initiatives.
  • Identify opportunities to simplify, standardize, and automate business processes across enterprise functions.
  • Support the design of scalable workflows and system-enabled processes that improve efficiency, accuracy, and consistency.
  • Translate business requirements into functional specifications and system configurations.
  • Ensure enterprise-system configurations and data-management practices support SOX, FDA, GDPR, and other regulatory requirements.
  • Partner with Internal Audit, Finance, HR, and IT to support audits, validation activities, and control improvements.
  • Support data integrity, reporting reliability, and appropriate access controls across enterprise systems.
  • Assist in maintaining reporting capabilities and scheduled report distribution for business stakeholders.
  • Act as a business partner to Finance and HR teams, helping align technology initiatives with operational priorities.
  • Drive user adoption through training, communication, and change-management activities.
  • Coordinate cross-functional collaboration across Finance, HR, IT, Compliance, and external vendors.
  • Manage vendor relationships to ensure service delivery meets business expectations.
  • Ensure enterprise-system initiatives are delivered on time and aligned with agreed priorities.
Desired Qualifications
  • Experience in the medical device, biotech, or pharmaceutical industry is preferred.
  • Workday experience is preferred.
  • PMP or Agile certification is preferred.
  • Professional certifications such as SHRM-SCP, HRCI, CPA, CMA, or CIA are preferred.
  • Exposure to change-management or process-improvement initiatives is preferred.
  • Familiarity with compliance and audit requirements in regulated environments is preferred.

About the company

TransMedics makes the Organ Care System (OCS), a portable platform that keeps donor organs alive outside the body by warm, oxygenated perfusion and continuous viability monitoring. The OCS circulates warmed, nutrient-rich blood through the organ, allowing surgeons to assess health in near-physiological conditions. Revenue comes from selling OCS consoles, disposable sets used per procedure, and the National OCS Program, which provides end-to-end organ retrieval and logistics services. It distinguishes itself by holding FDA approvals to preserve and assess hearts, lungs, and livers in the United States and by integrating hardware, consumables, and logistics to expand transplant opportunities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Andover, Massachusetts

Founded

1998

Get referred to TransMedics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 21% to $189.9 million, and guidance increased to $737-$757 million.
  • FDA approved ENHANCE Heart and DENOVO Lung IDEs in January-February 2026, advancing next-generation trials.
  • PAD Aviation closed July 6, 2026, opening pan-European transplant logistics contracts.

What critics are saying

  • Judge Sorokin partially denied dismissal July 21, 2026, forcing discovery in the fraud case.
  • CHOPS and kidney development burn cash while gross margin slipped to 60% in Q2 2026.
  • A bad ENHANCE or DENOVO safety signal in 2026-2027 would damage OCS credibility.

What makes TransMedics unique

  • FDA-approved OCS remains the only U.S. warm-perfusion platform for hearts, lungs, and livers.
  • The National OCS Program bundles surgeons, logistics, aircraft, and disposables into a sticky ecosystem.
  • PAD Aviation extends TransMedics' logistics moat into Europe, copying the U.S. NOP playbook.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Short Term Disability
  • Long Term Disability
  • Health Savings Account/Flexible Spending Account
  • Dependent Care Flexible Spending Account
  • 401(k) Plan
  • Pet insurance
  • Employee Stock Purchase Plan
  • Wellness Program

Growth & Insights and Company News

6 month growth

1%

1 year growth

1%

2 year growth

2%
Yahoo Finance
Oct 1st, 2026
TransMedics director buys $109K in stock amid 30% yearly decline

David Weill, a director at TransMedics Group, purchased 1,336 shares of common stock for approximately $109,000 on 11 September 2026, according to an SEC Form 4 filing. The purchase increased his direct holdings by 9% to 16,392 shares, valued at roughly $1.4 million. The transaction occurred as the stock recorded a one-year return of -30%. TransMedics, a commercial-stage medical technology company with a market capitalisation of $2.7 billion, develops the Organ Care System, a portable device that preserves and monitors donor organs for transplantation. The company reported trailing twelve-month revenues of $668.5 million and net income of $151.7 million. Management has guided for 22%-25% sales growth in 2026 as it expands internationally and develops new platforms.

Yahoo Finance
Sep 15th, 2026
TransMedics and SoFi stocks fall 28% and 34% but show strong buying potential

TransMedics Group and SoFi Technologies have declined 28% and 34% respectively over the past year, presenting potential buying opportunities despite broader market strength driven by tech giants. TransMedics, which developed the Organ Care System for transplants, faces near-term headwinds. Second-quarter revenue grew 21% year over year to $189.9 million, marking a slowdown from recent quarters. Adjusted earnings per share fell 52% to $0.44. However, the company is investing in expansion initiatives, including potential kidney transplant approval and a logistics network for greater control over the organ transplant cycle. These investments are pressuring current profits but could drive future growth. The OCS technology maintains organ temperature and blood supply during transport, addressing limitations of traditional cold storage methods. With a large addressable market remaining, the stock may offer value at current levels.

PR Newswire
Aug 4th, 2026
TransMedics reports 21% revenue growth to $190M in Q2 2026, raises guidance despite margin pressure

TransMedics Group reported second quarter 2026 revenue of $189.9 million, a 21% increase from $157.4 million in the prior year period. The growth was driven primarily by increased utilisation of the company's Organ Care System, particularly in liver and heart transplants through its National OCS Programme, as well as logistics services revenue. Gross margin decreased to 60% from 61% year-over-year, reflecting a higher mix of service revenue and temporary product-cost factors. Net income fell to $14.7 million, or $0.41 per diluted share, compared to $34.9 million, or $0.92 per share, in the second quarter of 2025. The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth. TransMedics develops portable extracorporeal warm perfusion technology for donor organ transplantation.

MarketScreener
Jul 6th, 2026
TransMedics invests in PAD Aviation to build Europe-wide organ transplant air logistics network

TransMedics Group has completed a strategic investment in PAD Aviation service GmbH, a Germany-based private aviation operator. The deal aims to establish a dedicated organ transplantation air logistics network across Europe, replicating TransMedics' OCS NOP model from the US. PAD Aviation, founded in 2006, operates from a 24/7 hub in Paderborn, Germany. The company maintains a fleet of nine Embraer Phenom 300 aircraft and employs over 40 pilots, holding a valid EASA Air Operator Certificate. TransMedics develops portable extracorporeal warm perfusion technology for preserving and assessing donor organs. The investment supports the company's efforts to expand adoption of its OCS perfusion technology and create a pan-European organ transport logistics network across the European Union.

Yahoo Finance
Jul 2nd, 2026
TD Cowen sets $120 target on TransMedics, sees 77% upside on transplant growth

TransMedics Group has received a 'Buy' rating from TD Cowen with a $120 price target, implying 77% upside from its last close. The firm cited growing US transplant activity in heart, liver and lung procedures as a key driver for the company's Organ Care System technology and logistics business. Monthly US transplant data showed volumes rose approximately 5% year-over-year in the second quarter of 2026. TransMedics generated $173.9 million in total revenue in the first quarter of 2026, up 21% year-over-year, with product revenue reaching $108 million and service revenue contributing $66 million. The company ended the quarter with $461.7 million in cash and cash equivalents. Shares closed up 2% on Wednesday and gained further in after-hours trading.

INACTIVE